CFI-402257 + Paclitaxel for Breast Cancer
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications, but there is a requirement for a 'washout period' (time without taking certain medications) for some treatments. It's best to discuss your specific medications with the trial team to see if they are allowed.
What data supports the effectiveness of the drug CFI-402257 + Paclitaxel for breast cancer?
Research shows that nab-paclitaxel (a form of paclitaxel) is effective in treating breast cancer, with higher response rates and better safety compared to traditional paclitaxel. It is approved for use in breast cancer after other treatments have failed, suggesting its potential effectiveness in combination with other drugs like CFI-402257.12345
Is the combination of CFI-402257 and Paclitaxel safe for humans?
The safety of nab-paclitaxel (Abraxane), a form of paclitaxel, has been studied and it generally shows a better safety profile with fewer severe side effects compared to traditional paclitaxel. It is approved for use in breast cancer treatment and has been shown to have less toxicity, such as a lower rate of severe neutropenia (a condition where there is a low count of a type of white blood cell), compared to solvent-based paclitaxel.12367
What makes the drug CFI-402257 + Paclitaxel unique for breast cancer treatment?
The drug CFI-402257 + Paclitaxel is unique because it uses a novel formulation of paclitaxel called nanoparticle albumin-bound paclitaxel (Abraxane), which does not require toxic solvents, leading to safer administration and potentially higher drug concentration in tumors, improving efficacy and reducing side effects compared to traditional paclitaxel formulations.13689
What is the purpose of this trial?
This trial tests a new drug, CFI-402257, combined with an existing chemotherapy drug, paclitaxel, in breast cancer patients. It aims to find the highest safe dose of CFI-402257 and evaluate if this combination works better than using paclitaxel by itself.
Research Team
Philippe Bedard
Principal Investigator
Princess Margaret Cancer Centre, Toronto, ON
Mihaela Mates
Principal Investigator
Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON
Eligibility Criteria
This trial is for adult women with advanced or metastatic HER2-negative breast cancer who have not responded well to non-taxane chemotherapy. They must be in good physical condition (ECOG 0 or 1), able to swallow pills, and willing to use effective contraception. Exclusions include previous taxane treatment in the metastatic setting, certain heart conditions, uncontrolled illnesses, known drug hypersensitivity, and recent major surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase I Treatment
Participants receive CFI-402257 with paclitaxel to determine the maximum tolerated dose
Phase II Treatment
Participants receive CFI-402257 with paclitaxel at the determined safe dose to evaluate its effect on breast cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CFI-402257
- Paclitaxel
Paclitaxel is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
Stand Up To Cancer
Collaborator
Canadian Breast Cancer Foundation
Collaborator
Ontario Institute for Cancer Research
Collaborator